Quick Answer
Eledon Pharmaceuticals, Inc. reported Operating Income Loss of -$43.00 million for the year ending 2023.
- Eledon Pharmaceuticals, Inc. showed an increase of +51.4% in Operating Income Loss from 2022 to 2023.
- This data is from Eledon Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 28, 2024.
- XBRL data for this metric is available from 2012 to 2023 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2012 to 2023), Eledon Pharmaceuticals, Inc.'s Operating Income Loss has declined by 345.6%.
- Historical annual values: Fiscal year 2023: -$43.00 million | Fiscal year 2022: -$88.43 million | Fiscal year 2021: -$36.87 million | Fiscal year 2020: -$18.47 million | Fiscal year 2019: -$16.05 million | Fiscal year 2018: -$14.06 million | Fiscal year 2017: -$13.12 million | Fiscal year 2016: -$5.13 million | Fiscal year 2015: -$45.26 million | Fiscal year 2014: -$23.46 million | Fiscal year 2013: -$15.75 million | Fiscal year 2012: -$9.65 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: